Protein and Cell Sciences, EMD Serono, 45A Middlesex Turnpike, Billerica, MA 01821, USA.
NBE Technologies, Merck Healthcare KGaA, Frankfurter Str. 250, 64293 Darmstadt, Germany.
Int J Mol Sci. 2024 Feb 8;25(4):2097. doi: 10.3390/ijms25042097.
The toolbox of modern antibody engineering allows the design of versatile novel functionalities exceeding nature's repertoire. Many bispecific antibodies comprise heterodimeric Fc portions recently validated through the approval of several bispecific biotherapeutics. While heterodimerization methodologies have been established for low-throughput large-scale production, few approaches exist to overcome the bottleneck of large combinatorial screening efforts that are essential for the identification of the best possible bispecific antibody. This report presents a novel, robust and miniaturized heterodimerization process based on controlled Fab-arm exchange (cFAE), which is applicable to a variety of heterodimeric formats and compatible with automated high-throughput screens. Proof of applicability was shown for two therapeutic molecule classes and two relevant functional screening read-outs. First, the miniaturized production of biparatopic anti-c-MET antibody-drug conjugates served as a proof of concept for their applicability in cytotoxic screenings on tumor cells with different target expression levels. Second, the automated workflow enabled a large unbiased combinatorial screening of biparatopic antibodies and the identification of hits mediating potent c-MET degradation. The presented workflow utilizes standard equipment and may serve as a facile, efficient and robust method for the discovery of innovative therapeutic agents in many laboratories worldwide.
现代抗体工程的工具包允许设计超越自然范围的多功能新型功能。许多双特异性抗体包含最近通过批准几种双特异性生物疗法验证的异二聚体 Fc 部分。虽然已经建立了用于低通量大规模生产的异二聚化方法,但很少有方法可以克服大规模组合筛选的瓶颈,这对于识别最佳双特异性抗体至关重要。本报告介绍了一种新颖、稳健和小型化的基于可控 Fab 臂交换 (cFAE) 的异二聚化工艺,该工艺适用于多种异二聚体格式,并与自动化高通量筛选兼容。两种治疗分子类别和两种相关功能筛选读出证明了适用性。首先,双价抗 c-MET 抗体药物偶联物的小型化生产可作为其在具有不同靶表达水平的肿瘤细胞上进行细胞毒性筛选的概念验证。其次,自动化工作流程能够对双价抗体进行大规模无偏组合筛选,并鉴定出介导有效 c-MET 降解的命中。所提出的工作流程利用标准设备,可作为全球许多实验室发现创新治疗剂的简便、高效和稳健方法。